Ruoslahti Research Laboratories at UC Santa Barbara and Sanford-Burnham
  • Upload

  • Log in

  • Sign up

Search on MyScienceWork
News Publications Members

Publication search

Sort by
  • Relevance
  • Published Date

Targeting atherosclerosis by using modular, multifunctional micelles

Peters, David Kastantin, Mark Kotamraju, Venkata Ramana Karmali, Priya P. Gujraty, Kunal Tirrell, Matthew Ruoslahti, Erkki

Published in Proceedings of the National Academy of Sciences of the United States of America

Subtle clotting that occurs on the luminal surface of atherosclerotic plaques presents a novel target for nanoparticle-based diagnostics and therapeutics. We have developed modular multifunctional micelles that contain a targeting element, a fluorophore, and, when desired, a drug component in the same particle. Targeting atherosclerotic plaques in ...

Cooperative nanomaterial system to sensitize, target, and treat tumors.

Jh, Park G, Von Maltzahn Mj, Xu V, Fogal Vr, Kotamraju E, Ruoslahti Sn, Bhatia Mj, Sailor

Published in Proceedings of the National Academy of Sciences

A significant barrier to the clinical translation of systemically administered therapeutic nanoparticles is their tendency to be removed from circulation by the mononuclear phagocyte system. The addition of a targeting ligand that selectively interacts with cancer cells can improve the therapeutic efficacy of nanomaterials, although these systems h...

Anoikis effector Bit1 negatively regulates Erk activity.

R, Kairouz-Wahbe H, Biliran X, Luo I, Khor M, Wankell C, Besch-Williford J, Pascual R, Oshima E, Ruoslahti

Published in Proceedings of the National Academy of Sciences

Bcl-2 inhibitor of transcription (Bit1) is a mitochondrial protein that functions as a peptidyl-tRNA hydrolase, but, when released into the cytoplasm, it elicits apoptosis. The proapoptotic function is uniquely counteracted by integrin-mediated cell attachment. We generated a conditional KO mouse of the Bit1 gene by using the Cre-LoxP recombination...

Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human an...

Sánchez-Martín, David Martínez-Torrecuadrada, Jorge Teesalu, Tambet Sugahara, Kazuki N Alvarez-Cienfuegos, Ana Ximénez-Embún, Pilar Fernández-Periáñez, Rodrigo Martín, M Teresa Molina-Privado, Irene Ruppen-Cañás, Isabel ...

Published in Proceedings of the National Academy of Sciences of the United States of America

Antibody cancer therapies rely on systemically accessible targets and suitable antibodies that exert a functional activity or deliver a payload to the tumor site. Here, we present proof-of-principle of in vivo selection of human antibodies in tumor-bearing mice that identified a tumor-specific antibody able to deliver a payload and unveils the targ...

Target-seeking antifibrotic compound enhances wound healing and suppresses scar formation in mice.

Järvinen, Tero A H Ruoslahti, Erkki

Published in Proceedings of the National Academy of Sciences of the United States of America

Permanent scars form upon healing of tissue injuries such as those caused by ischemia (myocardial infarction, stroke), trauma, surgery, and inflammation. Current options in reducing scar formation are limited to local intervention. We have designed a systemically administered, target-seeking biotherapeutic for scar prevention. It consists of a vasc...

Peptides targeting inflamed synovial vasculature attenuate autoimmune arthritis.

Yang, Ying-Hua Rajaiah, Rajesh Ruoslahti, Erkki Moudgil, Kamal D

Published in Proceedings of the National Academy of Sciences of the United States of America

Autoimmune diseases, such as rheumatoid arthritis, frequently target one major tissue/organ despite the systemic nature of the immune response. This is particularly perplexing in the case of ubiquitously distributed antigens invoked in arthritis induction. We reasoned that selective targeting of the synovial joints in autoimmune arthritis might be ...

Powered by Polaris
  • About the Lab
  • Our Research
  • About this Platform
  • FAQ